Ablation for atrial fibrillation: an evidence-based analysis
Record ID 32006000921
English
Authors' objectives:
At the request of the Ontario Health Technology Assessment Committee, the Medical Advisory Secretariat systematically reviewed the evidence of the effectiveness, safety, and costing of ablation methods to manage atrial fibrillation (AF). The ablation methods reviewed were catheter ablation and surgical ablation.
Authors' results and conclusions:
Sixteen RCTs were identified that compared ablation methods in patients with AF. Two studies were identified that investigated first-line therapy for AF or atrial flutter. Seven other studies examined patients with drug-refractory, lone AF; and the remaining 7 RCTs compared ablation plus heart surgery to heart surgery alone in patients with drug-refractory AF and concomitant heart conditions.
First-line Catheter Ablation for Atrial Fibrillation or Atrial Flutter
Both studies concluded that catheter ablation was associated with significantly improved long-term freedom from arrhythmias and quality of life compared with medical therapy. These studies included different patient populations (those with AF in one pilot study, and those with atrial flutter in the other). Catheter ablation as first-line treatment is considered experimental at this time.
Catheter Ablation Versus Medical Therapy in Patients With Drug-Refractory, Lone Atrial Fibrillation
In this review, catheter ablation had success rates (freedom from arrhythmia) that ranged from 42% to 90% (median, 74%) in patients with drug-refractory, lone AF. All 3 of the RCTs comparing catheter ablation to medical therapy in patients with drug-refractory, lone AF found a significant improvement in terms of freedom from arrhythmia over a minimum of 12 months follow-up (P<.05).
Ablation Plus Heart Surgery Versus Heart Surgery Alone in Patients With Atrial Fibrillation
It is clear that patients with drug-refractory AF who are undergoing concomitant heart surgery (usually mitral valve repair or replacement) benefit significantly from surgical ablation, in terms of long-term freedom from AF, without substantial additional risk compared to open heart surgery alone. This group of patients represents about 1% of the patients with atrial fibrillation, thus the majority of the burden of AF lies within the patients with lone AF (i.e. those not requiring additional heart surgery).
Authors' recommendations:
Catheter ablation appears to be an effective treatment for patients with drug-refractory AF whose treatment alternatives are limited. Ablation technology is continually evolving with increasing success rates associated with the ablation procedure.
Authors' methods:
Systematic review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/rev_af_030106.pdf
URL for additional information:
http://www.hqontario.ca/en/mas/mas_ohtas_tech_af_030106.html
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Catheter Ablation
- Atrial Fibrillation
Contact
Organisation Name:
Medical Advisory Secretariat
Contact Address:
Medical Advisory Secretariat, 20 Dundas Street West, 10th Floor, Toronto, ON M5G 2N6 CANADA. Tel: 416-314-1092l; Fax: 416-325-2364;
Contact Name:
MASinfo.moh@ontario.ca
Contact Email:
MASinfo.moh@ontario.ca
Copyright:
Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.